3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid
3
Leukemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Myeloproliferative Disorders
2
Bronchiolitis Obliterans Syndrome
2
Hematologic Diseases
1
HER2+ Metastatic Breast Cancer
1
Brain Neoplasms
1
Blast Crisis
1
Interventions
ponatinib
3
asciminib
3
nilotinib
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Specimen Handling
2
Melphalan
2
Dasatinib
2
Cyclophosphamide
2
Busulfan
2
venetoclax
1
ruxolitinib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
letermovir
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Stem Cell Transplantation
1
Sirolimus
1
Rituximab
1
Pharmaceutical Preparations
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methotrexate
1
Interviews as Topic
1
Imatinib Mesylate
1
Etoposide
1
Cyclosporine
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Chronic-Phase
×
asciminib
×
90 days
×
Clear all
NCT05143840
2026-06-02
ALERTCML
University of Alabama at Birmingham
Phase 2
Recruiting
100 enrolled
NCT03874858
2026-04-02
DANTE
Novartis
Phase 2
Completed
124 enrolled
NCT06368414
2026-04-02
AsterA
Korean Society of Hematology
Phase 2
Recruiting
69 enrolled